Elixinol Acquires 25% Stake in Pet Releaf

April 24, 2019

Elixinol purchased a 25% equity stake in Altmeds LLC, the maker of the Pet Releaf hemp‑derived CBD pet product line, to strengthen supply arrangements and provide growth capital to scale the business. The investment will fund working capital, new product lines and expansion of a new 25,000 sq. ft. production facility; Elixinol’s president will join the Pet Releaf board.

Buyers
Elixinol
Targets
Pet Releaf (Altmeds LLC)
Sellers
Alina and Steve Smith (founders of Pet Releaf)
Location
Colorado, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.